Browse the evidence

Maxillomandibular advancement (MMA) surgery achieves the largest and most durable reductions in OSA severity, with efficacy comparable to CPAP.

If you have severe sleep apnea and cannot use CPAP, ask about Maxillomandibular Advancement (MMA) surgery. It is a major surgery but can provide a permanent, CPAP-level reduction in apnea events for the right candidate.

There are confirmed cases of falsified GLP-1 receptor agonists in Brazil, indicating supply chain vulnerabilities.

Counterfeit GLP-1 drugs have been confirmed in Brazil. Patients should obtain medications through regulated channels to avoid falsified products.

The presence of anti-drug antibodies (ADAs) to GLP-1 receptor agonists does not necessarily neutralize their clinical efficacy, although it may increase the risk of hypersensitivity reactions.

If you develop antibodies to your GLP-1 medication, it does not automatically mean it has stopped working for weight loss. However, you may experience more injection site reactions. Discuss these symptoms with your doctor; they may not need to stop the drug unless side effects are severe.

Intensive lifestyle interventions (diet and exercise) alone are insufficient to prevent significant weight regain after discontinuation of incretin-based therapy, although they may modestly attenuate the rebound.

Even if you commit to intense diet and exercise after stopping your weight loss medication, you will likely regain a significant amount of weight. Lifestyle changes are important for your health, but they are not a substitute for the medication's hormonal effects in preventing regain.

GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.

GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.

GLP-1 receptor agonists (GLP-1RAs) cause frequent, dose-dependent gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation, reflux) that typically diminish over time but are a major cause of treatment discontinuation.

If you start a GLP-1 medication, expect digestive issues like nausea or diarrhea in the first few months. These symptoms are very common (affecting half to 60% of users) and are usually dose-dependent. The good news is that they typically get better over time. Starting with a lower dose and increasing slowly can help manage this.

GLP-1RAs are associated with an increased risk of hypoglycemia, particularly when combined with insulin or sulfonylureas, although the risk remains lower than with those agents alone.

If you take a GLP-1 medication along with insulin or sulfonylureas, your risk of low blood sugar (hypoglycemia) increases. However, this risk is still lower than if you were taking insulin or sulfonylureas alone. Monitor your blood sugar as advised by your doctor.

Sarcopenia is driven by anabolic resistance, mitochondrial dysfunction, and chronic inflammation, which decouple muscle mass from muscle function.

Understanding that muscle mass and function are different helps explain why you might look stronger but still feel weak. Treating the underlying inflammation and mitochondrial health is as important as building size.

Metabolic surgery (RYGB/VSG) improves glycemic control and induces T2DM remission through weight-loss-independent mechanisms, specifically by altering bile acid metabolism (FXR/TGR5 pathways), increasing incretin hormones (GLP-1/PYY), and modulating the gut microbiome, in addition to caloric restriction.

Metabolic surgery works by changing how your body processes food signals (hormones and bile acids), not just by making you eat less. This reset can lead to diabetes remission even before significant weight loss occurs, suggesting that the procedure alters the underlying biology of insulin resistance.

Metabolic surgery increases circulating levels of bile acids (BAs), which activate FXR and TGR5 receptors to suppress gluconeogenesis, improve insulin resistance, and stimulate GLP-1 secretion, thereby improving glucose homeostasis.

Surgery changes bile acid flow and concentration, which acts as a signaling molecule to tell the liver to stop producing excess sugar and to stimulate hormones that help insulin work better.

DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin) are cardiovascularly safe (neutral effect on MACE) but do not significantly reduce cardiovascular events or mortality compared to placebo.

DPP-4 inhibitors (like sitagliptin) are safe for your heart and do not increase the risk of heart attacks or strokes, but they also do not reduce these risks. They are a good option for blood sugar control if you cannot tolerate other drugs, but if you have existing heart disease, doctors usually prefer SGLT-2 inhibitors or GLP-1 agonists because those have proven heart benefits.

Adherence to a Mediterranean diet supplemented with extra-virgin olive oil or nuts does not significantly reduce the incidence of heart failure compared to a low-fat control diet in high cardiovascular risk individuals, although point estimates suggest a potential benefit that requires larger trials to confirm.

For individuals at high cardiovascular risk, following a Mediterranean diet supplemented with olive oil or nuts did not statistically significantly reduce the risk of developing heart failure compared to a low-fat diet in this specific trial. However, the trend favored the Mediterranean diet, and the study may have been underpowered. It remains a heart-healthy dietary pattern for other cardiovascular benefits, but should not be relied upon as a guaranteed prevention method for heart failure based on this data alone.

The RECODe risk equations provide more accurate predictions for microvascular and cardiovascular complications in diverse U.S. populations with type 2 diabetes compared to older models like UKPDS OM2 and ACC/AHA PCEs, which tend to substantially overestimate risk.

For clinicians managing diverse type 2 diabetes patients, using the RECODe risk equations instead of older models (like UKPDS or ACC/AHA PCEs) leads to more accurate risk assessment. This accuracy helps avoid unnecessary aggressive treatments for patients at lower actual risk and ensures high-risk patients receive appropriate intensive care, thereby reducing drug-related morbidity and improving overall population health management.

The Nutri-Score front-of-pack labeling system fails to identify unhealthy ultra-processed foods because it evaluates only nutrient composition and ignores the degree of food processing.

Do not rely solely on the Nutri-Score letter (A-E) to judge if a food is healthy. A product can receive an 'A' rating for nutrients but still be an ultra-processed food (NOVA 4) with additives and low nutritional value in terms of food matrix. Look for the degree of processing (NOVA classification) alongside or instead of Nutri-Score to make better choices.

Gluten-free diets do not appear to impact IBD disease activity, hospitalization, or surgery rates, despite many patients self-reporting symptom improvement.

For most IBD patients, a gluten-free diet does not reduce disease activity, hospitalizations, or surgery rates. While some patients report subjective symptom improvement, this does not translate to better clinical outcomes. It is not recommended as a primary treatment for IBD unless Celiac Disease is diagnosed.

The timing of daily metabolic responses to nutritional challenges differs significantly between serum and skeletal muscle, with serum metabolites showing robust time-of-day oscillations that are reprogrammed by diet type, whereas skeletal muscle metabolome shows less time-of-day variation.

For metabolic health, the timing of your meals matters as much as what you eat. Serum metabolites show strong daily oscillations that are reprogrammed by diet type (high fat vs high carb). While muscle metabolome is less responsive to time-of-day, serum shows significant differences between morning and evening states. This suggests that aligning meal timing with circadian rhythms may be a lever for metabolic optimization, particularly for lipid metabolism in the blood.

In low-income countries (LIC), the excess cardiovascular and all-cause mortality associated with diabetes remains high and is not significantly attenuated by standard pharmacological treatments (antidiabetes, antihypertensive, lipid-lowering drugs, and aspirin), unlike in high-income countries where treatment substantially reduces this risk.

For patients in low-income settings, having a diabetes diagnosis carries a significantly higher mortality risk than in wealthy nations, and simply taking prescribed medications (for blood sugar, blood pressure, or cholesterol) does not fully mitigate this risk. This is due to systemic issues like low medication adherence, suboptimal dosing, lack of access to acute cardiac care (like angioplasty), and socioeconomic disparities. To reduce mortality, access to care must be improved beyond just medication availability, including affordable acute interventions and better disease management.

Adhering to a low-carbohydrate diet (defined as the lowest quartile of carbohydrate intake, <42.7% of energy) is associated with a significantly higher risk of developing incident atrial fibrillation compared to higher carbohydrate intake, regardless of whether the replaced carbohydrates are substituted with animal or plant-based fats and proteins.

If you follow a low-carbohydrate diet, be aware that long-term adherence may be associated with a higher risk of developing atrial fibrillation (an irregular heart rhythm). This risk appears to exist regardless of whether you replace carbohydrates with animal or plant-based foods. If you have risk factors for heart disease or AF, consider discussing your carbohydrate intake with a healthcare provider to balance weight management goals with cardiac rhythm health.

A 6-month produce prescription program providing $60/month in vouchers for fruit and vegetables does not significantly improve glycemic control (HbA1c), blood pressure, or BMI in patients with diabetes compared to usual care.

For patients with diabetes, simply receiving vouchers for fruit and vegetables is not enough to lower blood sugar. To see health benefits, programs must ensure the voucher amount is sufficient for the patient's household size and include robust, ongoing nutritional education. Without these supports, financial incentives alone may fail to improve clinical outcomes.

Standard diagnostic biomarkers (BNP/NT-proBNP) are less reliable in obese patients with HF due to lower circulating levels caused by increased clearance by adipose tissue, requiring lower cut-off values for diagnosis.

If you are obese and have heart failure symptoms, standard blood tests for heart failure (BNP/NT-proBNP) might show lower levels than expected, even if you have the condition. Doctors should use lower thresholds to diagnose you. Do not assume a 'normal' result means you don't have heart failure if you have symptoms.

Novel antidiabetic agents, specifically SGLT-2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists, exert significant anti-inflammatory effects in the cardiovascular and renal systems, contributing to improved cardiorenal outcomes in type 2 diabetes.

If you have Type 2 Diabetes, ask your doctor about newer medications like SGLT-2 inhibitors or GLP-1 agonists. These drugs do more than just lower blood sugar; they actively reduce inflammation in your blood vessels and kidneys, which helps prevent heart attacks, strokes, and kidney failure. This benefit is independent of how well they control your glucose levels.

GLP-1 receptor agonists reduce cardiovascular inflammation by activating AMPK and CAMKKβ signaling pathways, leading to the downregulation of pro-inflammatory genes and increased SIRT6 expression.

This technical mechanism explains why GLP-1 drugs protect blood vessels. By activating specific cellular 'switches' (AMPK and SIRT6), these drugs turn off inflammatory genes in the vessel walls, preventing plaque buildup and stiffness.

DPP-4 inhibitors reduce systemic inflammation by suppressing the secretion of IL-6 and IL-1β and inhibiting NF-κB nuclear translocation, leading to improved endothelial function and plaque stabilization.

DPP-4 inhibitors (like sitagliptin) help stabilize heart disease plaques by reducing the inflammatory signals (IL-6, IL-1β) that attract immune cells to artery walls. This reduces the risk of plaque rupture and heart attacks.

The 'Dual Intervention Point' (DIP) model proposes that physiological regulation is weak within a 'zone of indifference' (dynamic equilibrium) but becomes strong only when fatness crosses upper or lower intervention points.

Your body's regulatory 'alarm bells' (hunger/satiety signals) may be quiet when you are within a normal weight range (zone of indifference). Strong physiological corrections only happen when you move significantly outside this range (crossing intervention points).